Yet again, Novo Nordisk, the daddy of diabetes therapy, announces the successful completion of a single-dose Phase 1 trial with an oral insulin code labled NN1954. Although the results...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)